Data Residency and AI in EU Pharma: Where Your SOPs Actually Live

Ask a vendor "is your AI hosted in Europe?" and you will almost always get a yes. Ask where the embeddings are computed, where the vector index is stored, where prompt logs are retained, and which subprocessor serves the inference endpoint at 3 a.m. when the primary region is saturated — and the answer gets considerably less crisp. For DACH pharma manufacturers and CDMOs, that gap is where data residency risk lives. Your SOPs, validation protocols, deviation records, and batch documentation are not just personal-data-adjacent; they are the intellectual property of your clients and the evidentiary backbone of your quality system.

Why residency is a GxP question, not just a privacy question

Most residency discussions default to GDPR. That matters — deviation reports name operators, training records name individuals, CAPA records contain investigator statements — and any transfer outside the EEA triggers Chapter V of Regulation (EU) 2016/679, with the transfer impact assessment discipline established after Schrems II (C-311/18). Swiss sites additionally sit under the revised FADP (revDSG, in force since September 2023), which mirrors much of the GDPR logic but runs its own adequacy list.

But the GxP dimension is separate and often ignored. EU GMP Annex 11 requires that regulated electronic records be available, readable, and retrievable throughout the retention period, and that the regulated entity retain control over the system regardless of who hosts it. Annex 11 §3 obliges a formal supplier assessment for service providers; §4.8 and §7 address data storage, backup, and protection. Where the data physically resides determines:

• Inspection access. Can you produce records for a Swissmedic, BfArM, AGES, or FDA inspector within the timeframe they expect — without a foreign subprocessor's ticket queue in the critical path?
• Legal seizure exposure. Third-country access regimes (notably the US CLOUD Act) apply to providers subject to that jurisdiction, irrespective of the datacenter's physical location. This is the point most "our region is Frankfurt" claims miss.
• Client confidentiality obligations. CDMO quality agreements routinely restrict where client documentation may be processed. An AI assistant that indexes client-specific SOPs inherits those restrictions.

The seven places your SOP content actually goes

A retrieval-augmented AI assistant is not one system. It is a pipeline, and each stage can have a different residency profile. Map all of them before you sign anything:

• Document ingestion and OCR. Scanned legacy SOPs often go through third-party OCR APIs. Ask explicitly.
• Chunking and embedding. Text is sent to an embedding model. If that model is a hosted API in another jurisdiction, your SOP text has left the EU — even though the resulting vectors are stored locally.
• Vector store / index. Vectors are not anonymised data. Embedding inversion research has repeatedly demonstrated that substantial source text can be reconstructed. Treat the index as containing the document.
• Inference (the LLM call). The retrieved chunks are placed in the prompt. This is the highest-volume egress of your actual SOP content.
• Prompt and completion logs. Vendor-side logging for "quality improvement" is the most common silent transfer. Retention periods here are frequently longer than your own record retention policy allows.
• Telemetry, error traces, and APM. Stack traces routinely carry payload fragments.
• Human review / support access. Support engineers with production read access in a third country constitute a transfer.

If you cannot draw the data flow on one page, naming the legal entity and country for each of these seven stages, you do not yet have a defensible residency position — you have a marketing claim.

EU AI Act adds a documentation layer

Under Regulation (EU) 2024/1689, an internal compliance assistant used for SOP question-answering is generally not high-risk in itself, but the transparency and technical documentation obligations for general-purpose AI models flow downstream to deployers. Article 53 requires model providers to document training data and downstream usage terms; as a deployer you need those artefacts in your own supplier file. Combine this with Annex 11 §3.2 (supplier audit) and GAMP 5 Second Edition's emphasis on leveraging supplier documentation rather than reinventing it. Residency, subprocessor lists, and model-provider documentation belong in the same supplier qualification package — not in three unconnected folders.

Practical requirements to write into your URS

Vague language fails audits. Specify:

• Processing geography, per stage. "All ingestion, embedding, indexing, inference, and logging occurs within EU/EEA or Swiss datacenters." Name the regions.
• Named subprocessors with change notification. A 30-day advance notice clause with a right to object. Silent subprocessor additions are a change control failure.
• No training on customer data. Contractually binding, not a settings toggle. Include a prohibition on human review of prompts and completions without a documented, per-incident authorisation from you.
• Log retention and deletion. Define retention for prompts, completions, and retrieval traces. Note the tension: your Annex 11 §9 audit trail must persist, but vendor-side debug logs need not. Separate the two.
• Encryption and key custody. AES-256 at rest, TLS 1.2+ in transit, and — where your client agreements demand it — customer-managed keys so that revoking the key renders the index unreadable.
• Exit and portability. Export of source documents, metadata, and audit trail in an open format. Annex 11 §16 (business continuity) and §17 (archiving) require that records survive the vendor relationship.
• Deployment options. Single-tenant EU hosting, private cloud, or on-premises for sites with air-gapped OT networks. Multi-tenant vector stores with shared indexes are a hard no for most CDMOs handling competing clients' documentation.

A CDMO example

A mid-size Swiss CDMO running sterile fill-finish for three clients wants an AI assistant over its SOP library. Two clients' quality agreements restrict processing of their documentation to Switzerland or the EEA; one US client additionally requires FDA inspection readiness with records retrievable on site. The workable design: single-tenant deployment in a Swiss or EU region, per-client index segregation with role-based retrieval filters, embeddings computed by a model running inside the same region, zero vendor-side prompt retention, and an audit trail exported nightly into the on-premises archive. The validation package then covers residency as a configuration item under change control — so moving a region becomes a documented change, not an incident discovered during an audit.

What QA should ask for before the pilot

• Data flow diagram with jurisdictions per stage
• Current subprocessor register and notification terms
• DPA with SCCs (if any residual transfer) plus a completed transfer impact assessment
• Model provider documentation per AI Act Article 53
• Penetration test summary and ISO 27001 scope statement — checking that the AI service is actually in scope
• Retention schedule for every log type

Residency is not a checkbox appended to a security questionnaire. It is a design constraint that determines whether your AI compliance layer can be validated at all — and it is far cheaper to specify up front than to retrofit after a client audit finding.

See how ComplianceGxP handles data residency and EU-hosted document processing for pharma and CDMO teams: See how it works →